背景:免疫介导的结膜炎是一种常见的眼部疾病,其特征是结膜中的炎症和免疫反应。然而,这种情况的确切原因和治疗方法仍然是众多眼科专家关注的重点。最近,从人类和小鼠实验中积累的证据已经证明了NLRP3炎性体的关键参与,IL-1β,和IL-18在过敏性疾病的发展中。靶向特异性NLRP3炎性体及其相关抑制剂可能具有作为免疫结膜炎治疗剂的潜力。尽管如此,尚无专门针对NLRP3相关的免疫性结膜炎治疗的系统评价.因此,本研究旨在对目前发表的关于NLRP3相关治疗免疫性结膜炎患者的随机对照试验(RCTs)进行系统评价和荟萃分析,目的是评估其疗效和安全性。
方法:我们将在包括PubMed在内的各种数据库中全面搜索NLRP3炎性体抑制剂或NLRP3相关治疗免疫性结膜炎的相关研究,EMBASE,科克伦图书馆,中国国家知识基础设施(CNKI),VIP,还有万方。搜索将包括从各自的开始日期到2023年7月的研究。将使用从符合条件的随机对照试验(RCT)中提取的数据进行荟萃分析,关注免疫性结膜炎的临床表现,血清或泪液样本中NLRP3相关因子的水平,生活质量结果,和不良事件。审查管理器5.4.1软件将用于荟萃分析,结果将使用随机效应或固定效应模型进行分析,取决于异质性的存在。将使用建议分级来评估证据的可靠性和质量,发展,和评估(等级)系统。
结果:这项研究的结果将为NLRP3相关治疗免疫性结膜炎的有效性和安全性提供有力和高质量的证据。这些证据将大大有助于我们了解与此类治疗相关的潜在益处和风险,并将帮助医疗保健专业人员做出有关免疫性结膜炎管理的明智决定。
结论:本研究是首次全面的荟萃分析,旨在评估NLRP3相关治疗免疫性结膜炎的疗效和安全性。这项研究的结果将为指导该疾病的临床治疗策略提供有价值的证据。结果预计将显著有助于理解NLRP3相关治疗的治疗潜力和安全性。为参与免疫性结膜炎患者护理的医疗保健专业人员提供有价值的见解。
背景:系统审查注册:注册编号为CRD42023437076的PROSPERO。
BACKGROUND: Immune-mediated conjunctivitis is a prevalent ocular ailment characterized by inflammation and immune reactions in the conjunctiva. However, the precise causes and therapeutic approaches for this condition remain the main focus for numerous ophthalmological specialists. Recently, accumulating evidence from human and mouse experiments has demonstrated the critical involvement of the NLRP3 inflammasome, IL-1β, and IL-18 in the development of allergic diseases. Targeting specific NLRP3 inflammasome and its related inhibitors may hold potential as therapeutic agents for immunologic conjunctivitis. Despite this, there has been no systematic
review specifically addressing the treatment of immunologic conjunctivitis related to NLRP3. Therefore, this study aims to conduct a systematic
review and meta-analysis of currently published randomized controlled trials (RCTs) on NLRP3-related treatments for immunologic conjunctivitis patients, with the goal of evaluating their efficacy and safety.
METHODS: We will conduct a comprehensive search for relevant studies on NLRP3 inflammasome inhibitors or NLRP3-related treatments for immunologic conjunctivitis in various databases including PubMed, EMBASE, Cochrane Library, China National Knowledge Infrastructure (CNKI), VIP, and Wanfang. The search will encompass studies from their respective inception dates to July 2023. A meta-analysis will be performed using data extracted from eligible randomized controlled trials (RCTs), focusing on the clinical manifestations of immunologic conjunctivitis, levels of NLRP3-related factors in serum or tear samples, quality of life outcomes, and adverse events.
Review Manager 5.4.1 software will be employed for the meta-analysis, and the results will be analyzed using either random-effects or fixed-effects models, depending on the presence of heterogeneity. The reliability and quality of evidence will be evaluated using the Grading of Recommendations, Development, and Evaluation (GRADE) system.
RESULTS: The findings of this study will yield robust and high-quality evidence regarding the efficacy and safety of NLRP3-related treatments for immunologic conjunctivitis. This evidence will contribute significantly to our understanding of the potential benefits and risks associated with such treatments and will assist healthcare professionals in making informed decisions regarding the management of immunologic conjunctivitis.
CONCLUSIONS: This study represents the first comprehensive meta-analysis aiming to evaluate the efficacy and safety of NLRP3-related treatments for immunologic conjunctivitis. The findings from this study will provide valuable evidence to guide clinical management strategies for this disease. The results are anticipated to significantly contribute to the understanding of the therapeutic potential and safety profile of NLRP3-related treatments, offering valuable insights for healthcare professionals involved in the care of patients with immunologic conjunctivitis.
BACKGROUND: Systematic
review registration: PROSPERO with registration number CRD42023437076.